A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study.

Inclusion Criteria:

• History (within the past 24 months) of allergic conjunctivitis.
• Willing to avoid contact lens wear for each of the study visits, immediately prior to study medication installation and for 10 minutes after installation of study drug.
• Contact lens wear should be stable and consistent for 3 months prior to Screening Visit (Day 1).
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Contraindications or hypersensitivity to the use of the study medication or its components.
• Inability or unwillingness to follow all study instructions and complete study visits as required.
• Subjects with only one sighted eye or not correctable (using ETDRS chart) to 0.6 log MAR or better in both eyes at the Screening Visit.
• A known history of recurrent corneal erosion syndrome (idiopathic or secondary to dry eye).
• Ocular trauma within six months prior to Visit 1 in either eye as determined by subject history and/or examination.
• Other protocol-defined exclusion criteria may apply.